Thus, according to these data and our own results, doxorubicin-induced NF-κB activation in a p53 defcient background might favor the acquisition of a metastatic phenotype of breast cancer, and residual cells after treatment would be more aggressive resulting in tumor promotion to dissemination. The gene discussed is NFKB1; the disease is neoplasm.